drug

ABT-925

MeSH C585125
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Abbott Medical Devices
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Investigational (via trials)
SchizophreniaSchizophrenia

Trials

1
An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia
NCT00412620Phase 2Terminated

KOLs & investigators

1
Beatrice Rendenbach-Mueller, PhD

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Abbott Medical Devices
company
trial
An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia
PHASE2
trial
indication
Schizophrenia
indication
Schizophrenia
indication
KOL
Beatrice Rendenbach-Mueller, PhD
KOL score —
person